Market Cap 1.24B
Revenue (ttm) 8.33M
Net Income (ttm) -89.30M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,072.03%
Debt to Equity Ratio 0.17
Volume 1,365,600
Avg Vol 3,129,314
Day's Range N/A - N/A
Shares Out 273.92M
Stochastic %K 42%
Beta 1.02
Analysts Strong Sell
Price Target $11.00

Company Profile

Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for t...

Industry: Biotechnology
Sector: Healthcare
Phone: 214 612 0000
Address:
3000 Pegasus Park Drive, Suite 1430, Dallas, United States
quickaspeter
quickaspeter Feb. 3 at 4:18 PM
$TSHA - Jefferies massively increased its position (up 4,105.3%) to 10,313,733 shares (~$23.8M), and institutional investors now own about 77.7% of the company. - SG Americas Securities LLC cut its stake in Taysha by 93.3% in Q3, selling 460,352 shares and leaving 32,949 shares valued at about $108,000. - Company insiders sold a total of 967,140 shares worth $4.51 million in the past 90 days — including CFO Kamran Alam (78,968 shares at $4.75) — leaving insiders with 3.78% ownership.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 3 at 3:24 PM
$TSHA RSI: 47.15, MACD: -0.1445 Vol: 0.24, MA20: 4.83, MA50: 5.05 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
1 · Reply
Quantumup
Quantumup Feb. 3 at 11:31 AM
Citizens reiterated $ACAD Market Outperform-$34 and said, Likely negative CHMP opinion on the trofinetide MAA for Rett syndrome slows expansion into the EU $TSHA $NGNE $AVXL Citizens added, Yesterday afternoon, Acadia announced a negative CHMP trend vote on its trofinetide MAA for Rett Syndrome after an oral explanation, and the company expects a negative CHMP opinion. The formal CHMP opinion is anticipated later in February, and management intends to seek a re-examination of the opinion should it be unfavorable. While this update is disappointing, exU.S. sales of trofinetide represent potential upside to our model and valuation.
0 · Reply
warren5677
warren5677 Feb. 2 at 10:48 PM
$TSHA Jefferies increased stake in TSHA by 4100%. Adds 10 million shares. https://www.marketbeat.com/instant-alerts/filing-taysha-gene-therapies-inc-tsha-shares-sold-by-sg-americas-securities-llc-2026-02-01/
0 · Reply
WoIfofWaIIst
WoIfofWaIIst Feb. 2 at 6:54 PM
$TSHA $IBRX $OPTT My picks this week ladies and gents GLTA
1 · Reply
WoIfofWaIIst
WoIfofWaIIst Feb. 2 at 6:54 PM
$TSHA - Wow this board is quite. Let’s wake this baby up
0 · Reply
Dark_Horse_Investments
Dark_Horse_Investments Jan. 30 at 12:52 AM
$TSHA Fellow ‘high conviction & deep due diligence’ TSHA longs… Been noodling on the following, as the co nears full dosing & eventually data maturation for BLA (biologics license application) submission, perhaps by Q4: a) in the camp that the most viable exit is an acquisition by big pharma or a specialty pharma; b) what ballpark market capitalization could TSHA achieve upon approval, and; c) ultimately who could be a potential acquirer & expected date for a transaction, Astellas (relinquished first rights to TSHA-102) (18 months)? Others & @ what price/market cap? Been pondering to whom this asset is the most attractive & best fit their strategic profile? It is not the traditional bp, eg MRK, PFE or Novo to name the usual suspects – it is somebody else! Furthermore, Sean Nolan, Suku Najandram & of course Paul Manning are experienced deal makers & thus expect they are sowing the field for the harvest. Kindly share your educated thoughts here for the benefit of all.
1 · Reply
Johnny_443
Johnny_443 Jan. 29 at 2:26 PM
$TSHA CEO Nolan just bought a new house.
1 · Reply
Aawilliam2003
Aawilliam2003 Jan. 28 at 4:41 PM
$TSHA vs $NGNE ??? Both look good, $NGNE way cheaper
3 · Reply
JoeNolff6
JoeNolff6 Jan. 28 at 3:08 PM
$TSHA what is happening?
1 · Reply
Latest News on TSHA
Why Is Taysha Gene Therapies Stock Trading Higher On Thursday?

May 29, 2025, 1:06 PM EDT - 8 months ago

Why Is Taysha Gene Therapies Stock Trading Higher On Thursday?


Taysha Gene Therapies Is Showing Promise For Rett Syndrome

Jan 27, 2025, 7:53 PM EST - 1 year ago

Taysha Gene Therapies Is Showing Promise For Rett Syndrome


What's Going On With Taysha Gene Therapies Stock Tuesday?

Jun 18, 2024, 11:42 AM EDT - 1 year ago

What's Going On With Taysha Gene Therapies Stock Tuesday?


Taysha: Initial Rett Syndrome Data Leads To Other 2024 Catalysts

Mar 20, 2024, 12:30 PM EDT - 2 years ago

Taysha: Initial Rett Syndrome Data Leads To Other 2024 Catalysts


quickaspeter
quickaspeter Feb. 3 at 4:18 PM
$TSHA - Jefferies massively increased its position (up 4,105.3%) to 10,313,733 shares (~$23.8M), and institutional investors now own about 77.7% of the company. - SG Americas Securities LLC cut its stake in Taysha by 93.3% in Q3, selling 460,352 shares and leaving 32,949 shares valued at about $108,000. - Company insiders sold a total of 967,140 shares worth $4.51 million in the past 90 days — including CFO Kamran Alam (78,968 shares at $4.75) — leaving insiders with 3.78% ownership.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 3 at 3:24 PM
$TSHA RSI: 47.15, MACD: -0.1445 Vol: 0.24, MA20: 4.83, MA50: 5.05 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
1 · Reply
Quantumup
Quantumup Feb. 3 at 11:31 AM
Citizens reiterated $ACAD Market Outperform-$34 and said, Likely negative CHMP opinion on the trofinetide MAA for Rett syndrome slows expansion into the EU $TSHA $NGNE $AVXL Citizens added, Yesterday afternoon, Acadia announced a negative CHMP trend vote on its trofinetide MAA for Rett Syndrome after an oral explanation, and the company expects a negative CHMP opinion. The formal CHMP opinion is anticipated later in February, and management intends to seek a re-examination of the opinion should it be unfavorable. While this update is disappointing, exU.S. sales of trofinetide represent potential upside to our model and valuation.
0 · Reply
warren5677
warren5677 Feb. 2 at 10:48 PM
$TSHA Jefferies increased stake in TSHA by 4100%. Adds 10 million shares. https://www.marketbeat.com/instant-alerts/filing-taysha-gene-therapies-inc-tsha-shares-sold-by-sg-americas-securities-llc-2026-02-01/
0 · Reply
WoIfofWaIIst
WoIfofWaIIst Feb. 2 at 6:54 PM
$TSHA $IBRX $OPTT My picks this week ladies and gents GLTA
1 · Reply
WoIfofWaIIst
WoIfofWaIIst Feb. 2 at 6:54 PM
$TSHA - Wow this board is quite. Let’s wake this baby up
0 · Reply
Dark_Horse_Investments
Dark_Horse_Investments Jan. 30 at 12:52 AM
$TSHA Fellow ‘high conviction & deep due diligence’ TSHA longs… Been noodling on the following, as the co nears full dosing & eventually data maturation for BLA (biologics license application) submission, perhaps by Q4: a) in the camp that the most viable exit is an acquisition by big pharma or a specialty pharma; b) what ballpark market capitalization could TSHA achieve upon approval, and; c) ultimately who could be a potential acquirer & expected date for a transaction, Astellas (relinquished first rights to TSHA-102) (18 months)? Others & @ what price/market cap? Been pondering to whom this asset is the most attractive & best fit their strategic profile? It is not the traditional bp, eg MRK, PFE or Novo to name the usual suspects – it is somebody else! Furthermore, Sean Nolan, Suku Najandram & of course Paul Manning are experienced deal makers & thus expect they are sowing the field for the harvest. Kindly share your educated thoughts here for the benefit of all.
1 · Reply
Johnny_443
Johnny_443 Jan. 29 at 2:26 PM
$TSHA CEO Nolan just bought a new house.
1 · Reply
Aawilliam2003
Aawilliam2003 Jan. 28 at 4:41 PM
$TSHA vs $NGNE ??? Both look good, $NGNE way cheaper
3 · Reply
JoeNolff6
JoeNolff6 Jan. 28 at 3:08 PM
$TSHA what is happening?
1 · Reply
stockmoe12
stockmoe12 Jan. 27 at 2:20 AM
$TSHA payday anytime … lets see
1 · Reply
stockmoe12
stockmoe12 Jan. 23 at 3:52 PM
0 · Reply
quickaspeter
quickaspeter Jan. 22 at 4:55 PM
$TSHA The big payday is coming…more patience required! 💥🚀💰💰
0 · Reply
stockmoe12
stockmoe12 Jan. 22 at 2:49 AM
$TSHA sec filing - Black rock added 1.5m new stocks so total 17.9m stocks https://ir.tayshagtx.com/static-files/95216980-2802-4caf-8edc-065fb4eaf346
0 · Reply
Dark_Horse_Investments
Dark_Horse_Investments Jan. 21 at 7:42 AM
$TSHA such selective click bait garbage by market beat : suku sells 200k shares. The piece of sheet hack piece neglected to report that suku added an extra 400k shares... Suku, Sean Nolan CEO and CFO all added shares... Just garbage clickbait.
0 · Reply
stockmoe12
stockmoe12 Jan. 20 at 9:28 PM
$TSHA .. looking good in red day
0 · Reply
stockmoe12
stockmoe12 Jan. 17 at 2:18 AM
$TSHA I'm still expecting buyout announcement before data in Q3/4… let’s see ..
0 · Reply
Glide1
Glide1 Jan. 16 at 7:25 PM
$TSHA  does anybody know why this stock continues to slide. It had nothing but positive news but continues to be scalped. I am besides myself trying to figure it out.
2 · Reply
stockmoe12
stockmoe12 Jan. 15 at 1:39 PM
$TSHA before ph3 data they want to tsie it out low price $OCUL .. tsha ph3 data coming q3/q4
0 · Reply
stockmoe12
stockmoe12 Jan. 15 at 1:37 PM
$TSHA $OCUL buyout…..
0 · Reply
stockmoe12
stockmoe12 Jan. 14 at 6:42 PM
$TSHA just looked into $NGNE safety data in the latest presentation .. looks like tsha is clear winner both in terms of safety and efficacy prospective.. lets see when is the buyout announcement coming!!!!!!! expecting like rgls
1 · Reply
stockmoe12
stockmoe12 Jan. 14 at 4:49 PM
$TSHA slow and steady shorts are getting toasted ….need badly a short squeeze..
0 · Reply